The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment of pulmonary arterial hypertension (PAH).
Sotatercept, which will be marketed under the brand name Winrevair® by Merck, is a first-of-its-kind drug designed to target the underlying biology of PAH by trapping proteins called activins that are overproduced in individuals with the condition.